Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

OBJECTIVE Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. Current treatment options are often ineffective or poorly tolerated. Recent observations have revealed mitochondrial hyperpolarization and enhanced Ca2+ fluxing in T cells from SLE patients. Rapamycin, a lipophilic macrolide antibiotic that regulates mitochondrial transmembrane potential and Ca2+ fluxing, has been used safely and effectively to treat renal transplant rejection since 1999. In addition, rapamycin has been shown to ameliorate T cell function and to prolong survival in lupus-prone MRL/lpr mice. We therefore undertook the present study to investigate whether rapamycin is beneficial in patients with SLE. METHODS Nine patients with clinically active SLE that had been treated unsuccessfully with other immunosuppressive medications began therapy with rapamycin, 2 mg/day orally. Disease activity was assessed with the British Isles Lupus Assessment Group (BILAG) score, SLE Disease Activity Index (SLEDAI), and requirement for prednisone therapy. Mitochondrial transmembrane potential and Ca2+ fluxing were assessed by flow cytometry. RESULTS In patients treated with rapamycin, the BILAG score was reduced by a mean +/- SEM of 1.93 +/- 0.9 (P = 0.0218), the SLEDAI by 5.3 +/- 0.8 (P = 0.00002), and concurrent prednisone use by 26.4 +/- 6.7 mg/day (P = 0.0062) compared with pre-rapamycin treatment. While mitochondrial hyperpolarization persisted, pretreatment cytosolic and mitochondrial Ca2+ levels and T cell activation-induced rapid Ca2+ fluxing were normalized in rapamycin-treated patients. CONCLUSION Rapamycin appears to be a safe and effective therapy for SLE that has been refractory to traditional medications. Mitochondrial dysfunction and Ca2+ fluxing could serve as biomarkers to guide decisions regarding future therapeutic interventions in SLE.

[1]  K. N. Bradley,et al.  In smooth muscle, FK506-binding protein modulates IP3 receptor-evoked Ca2+ release by mTOR and calcineurin , 2005, Journal of Cell Science.

[2]  C. Nakar,et al.  Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. , 2005, Cancer research.

[3]  G. Nagy,et al.  Nitric Oxide-Dependent Mitochondrial Biogenesis Generates Ca2+ Signaling Profile of Lupus T Cells , 2004, The Journal of Immunology.

[4]  G. Tsokos,et al.  T lymphocytes in systemic lupus erythematosus: an update , 2004, Current opinion in rheumatology.

[5]  M. Crow,et al.  Interferon-α in systemic lupus erythematosus , 2004 .

[6]  G. Nagy,et al.  Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. , 2004, Trends in immunology.

[7]  Jie Chen,et al.  A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. , 2002, Biochemical pharmacology.

[8]  A. Perl,et al.  Persistent Mitochondrial Hyperpolarization, Increased Reactive Oxygen Intermediate Production, and Cytoplasmic Alkalinization Characterize Altered IL-10 Signaling in Patients with Systemic Lupus Erythematosus1 , 2002, The Journal of Immunology.

[9]  M. Duchen.  Mitochondria and calcium: from cell signalling to cell death , 2000, The Journal of physiology.

[10]  P. Truffa-bachi,et al.  The impact of immunosuppressive drugs on the analysis of T cell activation. , 2000, Current medicinal chemistry.

[11]  A. Perl,et al.  Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling. , 1999, Journal of immunology.

[12]  G. Tsokos,et al.  TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. , 1995, Journal of immunology.

[13]  György Hajnóczky,et al.  Decoding of cytosolic calcium oscillations in the mitochondria , 1995, Cell.

[14]  L. Adams,et al.  Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. , 1994, Arthritis and rheumatism.

[15]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[16]  D. Symmons,et al.  Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus , 1988 .

[17]  A. Perl,et al.  Effector activity of OKT4+ and OKT8+ T-cell subsets in lectin-dependent cell-mediated cytotoxicity against adherent HEp-2 cells. , 1984, Cellular immunology.

[18]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[19]  G. Nagy,et al.  T- and B-cell abnormalities in systemic lupus erythematosus. , 2005, Critical reviews in immunology.

[20]  G. Crabtree,et al.  Lymphocyte calcium signaling from membrane to nucleus , 2005, Nature Immunology.

[21]  G. Nagy,et al.  Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. , 2004, Methods in molecular medicine.

[22]  A. Perl,et al.  Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. , 2002, Arthritis and rheumatism.